Clinical Trials Logo

Cholangitis clinical trials

View clinical trials related to Cholangitis.

Filter by:

NCT ID: NCT03545672 Completed - Clinical trials for Primary Biliary Cholangitis

Early Identification of Myocardial Impairment in PBC

EARLY-MYO-PBC
Start date: September 1, 2017
Phase:
Study type: Observational

Primary biliary cholangitis (PBC) is a chronic inflammatory liver disease leading to cirrhosis. Researches reported patients with PBC may involve abnormalities on skeleton, thyroid and exocrine glands. However, whether this autoimmune disease would cause cardiac impairment is scarcely investigated. Cardiovascular Magnetic Resonance(CMR) is recently developed as a reliable modality to evaluate the cardiac tissue characteristics and functions. This study aims to investigate the cardiac status in PBC patients based on CMR.

NCT ID: NCT03521297 Not yet recruiting - Clinical trials for Primary Biliary Cholangitis (PBC)

Probiotics in PBC Patients of Poor Response to UDCA

Start date: January 20, 2020
Phase: Phase 2
Study type: Interventional

The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor ursodeoxycholic acid (UDCA) response.

NCT ID: NCT03516006 Active, not recruiting - Clinical trials for Primary Sclerosing Cholangitis

Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Primary sclerosing cholangitis (PSC) is an idiopathic condition with intrahepatic cholangitis and fibrosis, leading to multifocal bile duct stricture. Its main clinical manifestations are chronic cholestatic lesions and is deemed as autoimmune liver disease. PSC are immune abnormalities that occurs in patients with genetic susceptibility. No other pathogenesis is revealed yet. Ursodeoxycholic acid is used as an empirical treatment, and there is no approved drug or a acceptable treatment regimen. The disease often progresses to liver decompensation and requires liver transplantation. In recent years, the clinical application of stem cell therapy has seen many important advances. Stem cells are characterized with properties of multiple differentiation, repair of damaged tissue and immuno-modulation. This study aims to employ UCMSCs to treat PSC patients and observe its efficacy and safety, and to explore the possible therapeutic mechanisms.

NCT ID: NCT03476993 Terminated - Clinical trials for Liver Cirrhosis, Biliary

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Start date: April 27, 2018
Phase: Phase 2
Study type: Interventional

BCD-085 is an innovative drug, anti-interleukin-17 monoclonal antibody. The aim of the study is to evaluate the efficacy and safety of BCD-085 in patients with primary biliary cholangitis (PBC).

NCT ID: NCT03445585 Recruiting - Liver Cancer Clinical Trials

Biobank for Cholestatic Liver Diseases.

Start date: January 2017
Phase:
Study type: Observational [Patient Registry]

This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).

NCT ID: NCT03422042 Completed - Clinical trials for Common Bile Duct Calculi

Short Duration Versus Fourteen Days Antibiotic in Common Bile Duct Cholangitis

Start date: August 13, 2017
Phase: N/A
Study type: Interventional

Common bile duct stone cholangitis is a potentially fatal condition, characterized by an obstruction and bacterial infection of biliary system. The principles of management are appropriate biliary drainage and systemic antibiotics. There has been limited data about appropriate time of antibiotics in patient with successful endoscopic drainage.

NCT ID: NCT03394924 Completed - Clinical trials for Primary Biliary Cholangitis

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Start date: December 27, 2017
Phase: Phase 2
Study type: Interventional

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis

NCT ID: NCT03394781 Terminated - Clinical trials for Primary Sclerosing Cholangitis

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Start date: January 22, 2018
Phase: Phase 2
Study type: Interventional

This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).

NCT ID: NCT03359174 Terminated - Clinical trials for Cholangitis, Sclerosing

An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis

Start date: May 29, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine whether a low dose of ATRA will improve laboratory tests of liver and bile duct inflammation in patients with PSC. The investigators will also look for changes to other blood tests which are related to inflammation, scarring, and the immune system.

NCT ID: NCT03345589 Recruiting - Clinical trials for Primary Biliary Cholangitis

A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis

Start date: January 30, 2018
Phase: Phase 4
Study type: Interventional

This study evaluates the effect of 18-22mg/kg/d Ursodeoxycholic in refractory Primary Biliary Cholangitis